CTLT / Catalent, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36587 Catalent, Inc. (Exact name of registrant as specified in its

Changes in Control of Registrant, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 18, 2024 (December 18, 2024) CATALENT, INC.

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on December 30, 2024, pursuant to the provisions of Rule 12d2-2 (a).

Novo Holdings Completes Acquisition of Catalent Catalent to Strengthen its Leading Position as a Global Service Provider for the Pharma and Biotech Industry under Private Ownership

Exhibit 99.1 Novo Holdings Completes Acquisition of Catalent Catalent to Strengthen its Leading Position as a Global Service Provider for the Pharma and Biotech Industry under Private Ownership SOMERSET, NJ and COPENHAGEN, Denmark – December 18, 2024 – Catalent, Inc. (“Catalent”), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“N

[Remainder of Page Intentionally Left Blank]

Exhibit 10.1 [DATE], 2024 [NAME] VIA EMAIL Dear [NAME]: This letter agreement (this “Agreement”) confirms the agreement between you and Catalent, Inc. (the “Company”) regarding certain payments that you may become entitled to receive in connection with the acquisition (the “Acquisition”) of the Company by Creek Parent, Inc., pursuant to that certain Agreement and Plan of Merger, dated as of Februa

As filed with the Securities and Exchange Commission on December 18, 2024

As filed with the Securities and Exchange Commission on December 18, 2024 Registration No.

SEVENTH AMENDED AND RESTATED CATALENT, INC. A Delaware Corporation

Exhibit 3.2 SEVENTH AMENDED AND RESTATED BYLAWS OF CATALENT, INC. A Delaware Corporation TABLE OF CONTENTS Page ARTICLE I OFFICES Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS Section 1. Place of Meetings 1 Section 2. Annual Meetings 1 Section 3. Special Meetings 2 Section 4. Notice 2 Section 5. Adjournments and Postponements 2 Section 6. Quorum 3 Se

As filed with the Securities and Exchange Commission on December 18, 2024

As filed with the Securities and Exchange Commission on December 18, 2024 Registration No.

As filed with the Securities and Exchange Commission on December 18, 2024

As filed with the Securities and Exchange Commission on December 18, 2024 Registration No.

As filed with the Securities and Exchange Commission on December 18, 2024

As filed with the Securities and Exchange Commission on December 18, 2024 Registration No.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 14, 2024 CATALENT, INC.

Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction Transaction Expected to Close in the Coming Days

Exhibit 99.1 Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction Transaction Expected to Close in the Coming Days SOMERSET, NJ and COPENHAGEN, Denmark – December 14, 2024 – Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global li

Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction Transaction Expected to Close Towards the End of Calendar Year 2024

Exhibit 99.1 Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction Transaction Expected to Close Towards the End of Calendar Year 2024 SOMERSET, N.J. and COPENHAGEN, Denmark – December 6, 2024 – Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 6, 2024 (December 6, 2024) CATALENT, INC.

CTLT / Catalent, Inc. / NOMURA HOLDINGS INC Passive Investment

SC 13G/A 1 sayw2411142213ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Catalent, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 148806102 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropria

CTLT / Catalent, Inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Catalent, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 148806102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 20

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-36587 (Commission File Number) Catalent, Inc. (Exact name of r

Catalent, Inc. Reports First Quarter Fiscal 2025 Results

Exhibit 99.1 Investor Contact: Catalent, Inc. Paul Surdez 732-537-6325 [email protected] Catalent, Inc. Reports First Quarter Fiscal 2025 Results •Q1'25 net revenue of $1.02 billion increased 4% as reported and in constant currency(1), compared to Q1'24. •Q1'25 net revenue, excluding COVID revenue of ~$30 million in Q1’25 and ~$100 million in Q1'24, increased 13% compared to Q1'24. •Q1'25 net

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2024 CATALENT, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended June 30, 2024 or ☐ TRANSITION REPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE S ECU RITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36587 CATALEN

Offer letter, dated June 8, 2023, by and between Catalent, Inc. and Lisa Evoli.†*

Exhibit 10.17 June 8, 2023 Lisa Evoli Dear Lisa: Congratulations on this offer to join our team! Catalent hires people with a passion to make a difference to the health of millions of people globally. Your expertise, coupled with Catalent’s expertise and capabilities and its collaborations with thousands of innovative pharmaceutical, biotech, and healthcare companies, will help us develop, supply,

Offer letter, dated August 25, 2023, by and between Catalent, Inc. and David McErlane.†*

Exhibit 10.18 August 25, 2023 David McErlane Dear David, Congratulations on this offer to join our team! Catalent hires people with a passion to make a difference to the health of millions of people globally. Your expertise, coupled with Catalent’s expertise and capabilities and its collaborations with thousands of innovative pharmaceutical, biotech, and healthcare companies, will help us develop,

Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close Alessandro Maselli to Remain President and

EX-99.1 Exhibit 99.1 Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close Alessandro Maselli to Remain President and CEO of Catalent Post-Close SOMERSET, N.J. – Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of bet

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 21, 2024 (October 21, 2024)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 21, 2024 (October 21, 2024) CATALENT, INC.

Insider Trading Policy**

Insider Trading Policy Version 2.0 Date Issued: January 29, 2020 Issued By: Audit Committee of the Catalent, Inc. Board of Directors Catalent Insider Trading Policy v.2 This is a Catalent Inc. Policy and is not to be used or reproduced, other than for Catalent business purposes. Effective 29 January 2020 1. BACKGROUND This Insider Trading Policy (this “Policy”) sets forth the restrictions, guideli

Amendment to Registration Rights Agreement, dated as of April 17, 2024, by and among Catalent, Inc., Green Equity Investors VII, L.P., Green Equity Investors Side VII, L.P., LGP Associates VII-A LLC and LGP Associates VII-B LLC **

Execution Version AMENDMENT TO REGISTRATION RIGHTS AGREEMENT This AMENDMENT (this "Amendment") is made as of April 17, 2024 by and among Catalent, Inc.

Subsidiaries of the Registrant. **

Exhibit 21.1 Attachment A CATALENT, INC. SUBSIDIARIES As of June 30, 2024 NAME (STATE/COUNTRY OF ORGANIZATION) WHOLLY OWNED SUBSIDIARIES OF CATALENT, INC. (UNLESS OTHERWISE INDICATED) 1 Catalent Anagni S.r.l. (ITALY) 2 Catalent Argentina S.A.I.C. (ARGENTINA) 3 Catalent Belgium S.A. (BELGIUM) 4 Catalent Belgium Holding S.A. (BELGIUM) 5 Catalent Brasil Ltda (BRAZIL) 6 Catalent China Holdings Limited

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36587 CATALENT, INC. (Exact name of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one):  ☒ Form 10-K  ☐ Form 20-F  ☐ Form 11-K  ☐ Form 10-Q ☐ Form 10-D  ☐ Form N-CEN  ☐ Form N-CSR For Period Ended: June 30, 2024 ☐

SEC FILE NUMBER 001-36587 CUSIP NUMBER   148806102 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 29, 2024 CATALENT, INC.

Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results

Exhibit 99.1 Investor Contact: Catalent, Inc. Paul Surdez 732-537-6325 [email protected] Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results •Q4'24 net revenue of $1.30 billion increased 23% as reported, or 24% in constant currency, compared to Q4'23. Organic, constant-currency net revenue increased 24%, compared to Q4'23. ◦Q4'24 net revenue, excluding COVID-related revenue of ~$70

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 29, 2024 (May 29, 2024) CATALENT, INC.

Catalent Stockholders Approve Transaction with Novo Holdings

Exhibit 99.1 Catalent Stockholders Approve Transaction with Novo Holdings SOMERSET, N.J. – May 29, 2024- Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its Special Meeting of Stockholders (the “Special Meeting”) held earlier today, its stockholders voted to approve the pending transactio

Form Retention Agreement

Exhibit 10.1 SPECIAL RETENTION AWARD AGREEMENT [•] , 2024 [Name] Dear [Name]: As you may know, Catalent, Inc. (together with its successors, the “Company”) has entered into the Agreement and Plan of Merger, dated as of February 5, 2024 (the “Merger Agreement”), by and among the Company, Creek Parent, Inc. (“Parent”), and Creek Merger Sub, Inc. (“Merger Sub”). The Merger Agreement contemplates the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2024 CATALENT, INC.

CTLT / Catalent, Inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Catalent, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 148806102 (CUSIP Number) April 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2024 CATALENT, INC.

EMPLOYMENT AGREEMENT (John Greisch)

EMPLOYMENT AGREEMENT (John Greisch) This EMPLOYMENT AGREEMENT (the “Agreement”), dated August 28, 2023, is being entered into by and between Catalent, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-36587 (Commission File Number) Catalent, Inc. (Exact name of regis

Catalent, Inc. Reports Third Quarter Fiscal 2024 Results

Exhibit 99.1 Investor Contact: Catalent, Inc. Paul Surdez 732-537-6325 [email protected] Catalent, Inc. Reports Third Quarter Fiscal 2024 Results •Q3'24 net revenue of $1.07 billion increased 4% as reported, or 3% in constant currency(1), compared to Q3'23. •Q3'24 net revenue, excluding COVID-related revenue of ~$120 million in Q3’23 and ~$60 million in Q3’24, increased 11% compared to Q3'23.

December 22, 2023 {Revised}

Catalent. December 22, 2023 {Revised} Michael Hatzfeld 54152 Deer Ridge Court Rochester Ml 48307 Dear Michael: Congratulations on your offer to join our growing team! Catalent hires people with a passion to make a difference to the health of millions of people globally. Your expertise, coupled with Catalent's advanced technologies and collaboration with thousands of innovative pharmaceutical, biot

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 3, 2024 (May 2, 2024) CATALENT, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 3, 2024 (May 2, 2024) CATALENT,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 3, 2024 (May 2, 2024) CATALENT, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)). ☒ De

As filed with the Securities and Exchange Commission on April 9, 2024

S-8 As filed with the Securities and Exchange Commission on April 9, 2024 Registration No.

Filing Fee Table.

Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Catalent, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $.01

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)). ☐ De

CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Catalent, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation  Proposed Maximum  Aggregate Value of Transaction Fee  Rate   Amount of  Filing Fee Fees to

EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Catalent, Inc.

Letter from Ernst & Young LLP, dated March 1, 2024

Exhibit 16.1 March 1, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated March 1, 2024, of Catalent, Inc. and are in agreement with the statements contained in paragraphs two through four under (a) Dismissal of Independent Registered Public Accounting Firm therein. We have no basis to agree or disagree with other

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 CATALENT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36587 20-8737688 (State or other jurisdiction of incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 202

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-36587 (Commission File Number) Catalent, Inc. (Exact name of re

CTLT / Catalent, Inc. / NOMURA HOLDINGS INC Passive Investment

SC 13G 1 sayw2402144313g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Catalent, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 148806102 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate bo

TERMINATION AGREEMENT (within the meaning of Section 7:670b(1) of the Dutch Civil Code, in conjunction with Section 7:900 of the Dutch Civil Code)

Exhibit 10.3 Valid up to December 22, 2023 TERMINATION AGREEMENT (within the meaning of Section 7:670b(1) of the Dutch Civil Code, in conjunction with Section 7:900 of the Dutch Civil Code) THE UNDERSIGNED: 1.Catalent Pharma Solutions GmbH, a private limited liability company incorporated under Swiss law, having its registered office in Cham, Switzerland, and maintaining a place of business at Rie

CTLT / Catalent, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Catalent Inc Title of Class of Securities: Common Stock CUSIP Number: 148806102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 1

CTLT / Catalent, Inc. / Veritas Asset Management LLP Passive Investment

SC 13G/A 1 veritas-ctlt123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Catalent, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 148806102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one):  ☐ Form 10-K  ☐ Form 20-F  ☐ Form 11-K  ☒ Form 10-Q ☐ Form 10-D  ☐ Form N-CEN  ☐ Form N-CSR For Period Ended: December 31, 20

OMB APPROVAL OMB NUMBER 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response 2.

CTLT / Catalent, Inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Catalent, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 148806102 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2024 CATALENT, INC.

Catalent, Inc. Reports Second Quarter Fiscal 2024 Results

Exhibit 99.1 Investor Contact: Catalent, Inc. Paul Surdez 732-537-6325 [email protected] Catalent, Inc. Reports Second Quarter Fiscal 2024 Results •Q2'24 net revenue of $1.03 billion decreased 10% as reported, or 11% in constant currency(1), compared to Q2'23. •Q2'24 net revenue, excluding COVID-related revenue of ~$260 million in Q2’23 and ~$75 million in Q2’24, increased 8% compared to Q2'2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒     Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive

Novo Holdings to Acquire Catalent Catalent Stockholders to Receive $63.50 Per Share in Cash, Representing a 47.5% Premium to the 60-day Volume-Weighted Average Price as of February 2, 2024

Exhibit 99.1 Novo Holdings to Acquire Catalent Catalent Stockholders to Receive $63.50 Per Share in Cash, Representing a 47.5% Premium to the 60-day Volume-Weighted Average Price as of February 2, 2024 COPENHAGEN, Denmark and SOMERSET, N.J. – February 5, 2024 – Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holding

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 5, 2024 (February 5, 2024)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 5, 2024 (February 5, 2024) CATALENT, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 5, 2024 (February 5, 2024)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 5, 2024 (February 5, 2024) CATALENT, INC.

Agreement and Plan of Merger, dated as of February 5, 2024, by and among the Company, Parent and Merger Sub.

Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among: CREEK PARENT, INC., CREEK MERGER SUB, INC. and CATALENT, INC. Dated as of February 5, 2024 TABLE OF CONTENTS ARTICLE I THE MERGER Section 1.01 The Merger 2 Section 1.02 Closing 2 Section 1.03 Effective Time 2 Section 1.04 Effects of the Merger 3 Section 1.05 Organizational Documents of the Surviving Corporation 3 Section 1.06

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2024 (January 25, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2024 (January 25, 2024) CATALENT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36587 20-8737688 (State or other jurisdiction of incorporation)

Amendment No. 1 to Catalent, Inc. 2018 Omnibus Incentive Plan

EX-10.1 Exhibit 10.1 AMENDMENT NO. 1 TO THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN WHEREAS, Catalent, Inc. (the “Company”) maintains the Catalent, Inc. 2018 Omnibus Incentive Plan (the “Plan”) (capitalized terms not defined herein shall have the meaning assigned to such terms in the Plan); WHEREAS, pursuant to Section 13 of the Plan, the Board may amend the Plan; provided that amendments must

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 16, 2024 (January 11, 2024)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 16, 2024 (January 11, 2024) CATALENT, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Catalent Announces Closing of Incremental Term Loans

Exhibit 99.1 PRESS RELEASE Catalent Announces Closing of Incremental Term Loans SOMERSET, N.J., December 19, 2023 — Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that its wholly owned subsidiary, Catalent Pharma Solutions, Inc., as borrower, and certain other wholly owned subsidiaries of Catalent, entered

Amendment No. 11 to Amended and Restated Credit Agreement, dated as of December 19, 2023, by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JPMorgan Chase Bank, N.A., as the administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto, which amends that certain Amended and Restated Credit Agreement, dated as of May 20, 2014 (as amended), by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JPMorgan Chase Bank, N.A., as the successor administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto.

Exhibit 10.1 AMENDMENT NO. 11 TO AMENDED AND RESTATED CREDIT AGREEMENT AMENDMENT NO. 11 TO AMENDED AND RESTATED CREDIT AGREEMENT, dated as of December 19, 2023 (this “Amendment”), by and among CATALENT PHARMA SOLUTIONS, INC., a Delaware corporation (the “Borrower”), PTS INTERMEDIATE HOLDINGS LLC, a Delaware limited liability company (“Holdings”), the GUARANTORS, JPMORGAN CHASE BANK, N.A., as Admin

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 19, 2023 CATALENT, INC.

Paul Surdez, Catalent, Inc.

EX-99.1 Exhibit 99.1 PRESS RELEASE Investor Contact: Paul Surdez, Catalent, Inc. (732) 537-6325 [email protected] Catalent Regains Compliance with NYSE Continued Listing Standards December 15, 2023 SOMERSET, N.J.— Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT) announced today that the Company has received written notification (“Notice”) from the New York Stock Exchange (“NYSE”) tha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2023 (December 11, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2023 (December 11, 2023) CATALENT, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  ☒       Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 8, 2023 (August 29, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 8, 2023 (August 29, 2023) CATALENT, INC.

May 1

Exhibit 10.17.1 May 1st, 2023 Ricky Hopson Dear Ricky: Thank you for accepting this interim assignment crucial to the future of Catalent. Your expertise, coupled with Catalent’s capabilities and collaborations with thousands of innovative pharmaceutical, biotech, and healthcare companies, will help us develop, supply, and deliver billions of doses of life-enhancing products. Attached is important

July 1, 2022

Exhibit 10.17 July 1, 2022 Ricky Hopson Dear Ricky: Congratulations on your promotion to President, Division Head, Clinical Development & Supply. This letter amends and restates previous offer letters and is effective July 1, 2022. The following is important information about your new position, benefits and rewards. I encourage you to review all materials thoroughly and contact me with questions.

OPTION AGREEMENT UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN

Exhibit 10.6.3 OPTION AGREEMENT UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN Pursuant to the Option Grant Notice (the “Grant Notice”) delivered to the Participant (as defined in the Grant Notice), and subject to the terms of this Option Agreement, including, as applicable, any special terms and conditions for the Participant’s country set forth in Appendix 1 attached hereto (collectively,

- 2 -

Exhibit 10.8.1 14 Schoolhouse Road Somerset, NJ 08873 T (732) 537-6200 www.catalent.com October 10, 2022 Manja Boerman PRIVATE AND CONFIDENTIAL Long Term International Assignment Dear Manja, We are pleased to offer you an international assignment from the Netherlands to the United States with Catalent Pharma Solutions LLC. We trust this will be a mutually beneficial experience for you as well as f

EX-10.17 2

Exhibit 10.7.2 August 14, 2023 Dear Ricky, To facilitate a smooth transition and assimilation of the new CFO (hired on July 5, 2023), we have extended your interim stipend allowance of $20,000 per month through August 31, 2023. Please signify your acceptance of this adjustment to your compensation of employment by scanning/emailing a signed/dated copy of this offer letter to my attention. Sincerel

Catalent, Inc. Consolidated Statements of Operations (Unaudited; dollars and shares in millions, except per share data)

Exhibit 99.1 Revised Financial Highlights The financial tables in this Exhibit 99.1 reflect revisions to preliminary reported financial results for the three months and fiscal year ended June 30, 2023 related to identified revisions as noted in the Form 8-K/A filed December 8, 2023 (the “Form 8-K/A”). Fourth Quarter 2023 Segment Review (Dollars in millions) Three Months Ended June 30, Constant Cur

[Executive Name]

Exhibit 10.9 [DATE] [Executive Name] [Executive Home Address] Re: Severance Benefits Dear [first name], This letter will memorialize the severance payments and benefits to which you will be entitled if your employment with Catalent Pharma Solutions, LLC (the “Company”) ceases under specified circumstances. This letter is effective as of [DATE][, the date of your [promotion][commencement of employm

CATALENT, INC. SUBSIDIARIES As of June 30, 2023

Exhibit 21.1 Attachment A CATALENT, INC. SUBSIDIARIES As of June 30, 2023 NAME (STATE/COUNTRY OF ORGANIZATION) WHOLLY OWNED SUBSIDIARIES OF CATALENT, INC. (UNLESS OTHERWISE INDICATED) 1 Catalent Anagni S.r.l. (ITALY) 2 Catalent Argentina S.A.I.C. (ARGENTINA) 3 Catalent Belgium S.A. (BELGIUM) 4 Catalent Belgium Holding S.A. (BELGIUM) 5 Catalent Brasil Ltda (BRAZIL) 6 Catalent China Holdings Limited

RESTRICTED STOCK UNIT AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN

Exhibit 10.6.1 RESTRICTED STOCK UNIT AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN Pursuant to the Restricted Stock Unit Grant Notice for Non-Employee Directors (the “Grant Notice”) delivered to the Participant (as defined in the Grant Notice), and subject to the terms of this Restricted Stock Unit Agreement for Non-Employee Directors (the “Restricted St

[Executive Name]

Exhibit 10.9.1 [Date] [Executive Name] [Address] Re: Severance Benefits Dear [name]: This letter will memorialize the severance payments and benefits to which you will be entitled if your employment with Catalent Pharma Solutions, Inc. or its subsidiaries (the “Company”) ceases under specified circumstances and provided certain conditions set forth herein are satisfied. This letter is effective as

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36587 CATALENT, INC. (Exact name of

RESTRICTED STOCK UNIT AGREEMENT UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN

Exhibit 10.6.2 RESTRICTED STOCK UNIT AGREEMENT UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN Pursuant to the Restricted Stock Unit Grant Notice (the “Grant Notice”) delivered to the Participant (as defined in the Grant Notice), and subject to the terms of this Restricted Stock Unit Agreement, including, as applicable, any special terms and conditions for the Participant’s country set forth

EMPLOYMENT AGREEMENT

Exhibit 10.18 EMPLOYMENT AGREEMENT THE UNDERSIGNED: Catalent Pharma Solutions GmbH, having its registered office and maintaining a place of business at Riedstrasse 1 in 6330 Cham, Switzerland (the ‘Employer’), lawfully represented by Fréderic Gilot, its Director under the Articles of Association (statutair directeur); AND Ms. M. Boerman, residing (the ‘Employee’); WHEREAS: •By signing this employm

PERFORMANCE SHARE UNIT AGREEMENT UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN (Performance Period commencing on July 1, ____ and ending on June 30, ____)

Exhibit 10.6.4 PERFORMANCE SHARE UNIT AGREEMENT UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN (Performance Period commencing on July 1, and ending on June 30, ) Pursuant to the Performance Share Unit Grant Notice (the “Grant Notice”) delivered to the Participant (as defined in the Grant Notice), and subject to the terms of this Performance Share Unit Agreement, including, as applicable, any

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 20

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-36587 (Commission File Number) Catalent, Inc. (Exact name of r

CATALENT, INC. EXECUTIVE INCENTIVE COMPENSATION RECOUPMENT POLICY

Exhibit 97.1 CATALENT, INC. EXECUTIVE INCENTIVE COMPENSATION RECOUPMENT POLICY Version: v1 Date Issued: October 25, 2023 Issued By: Catalent Legal & Compliance Department Exhibit 97.1 1.Scope This policy applies to any (i) current or former Executive Officer and (ii) any other employee of the Company and its subsidiaries designated by the Committee as subject to this Policy from time to time. 2. P

Catalent, Inc. Consolidated Statements of Operations (Unaudited; dollars and shares in millions, except per share data)

Exhibit 99.2 Revised Financial Highlights The financial tables in this Exhibit 99.2 reflect revisions to preliminary reported financial results for the three months ended September 30, 2023 related to identified revisions as noted in the Form 8-K/A filed December 8, 2023 (“the Form 8-K/A”). First Quarter 2024 Segment Review (Dollars in millions) Three Months Ended September 30, Constant Currency 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 27, 2023 (November 22, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 27, 2023 (November 22, 2023) CATALENT, INC.

Amendment No. 10 to Amended and Restated Credit Agreement, dated as of November 22, 2023, by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JPMorgan Chase Bank, N.A., as the administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto, which amends that certain Amended and Restated Credit Agreement, dated as of May 20, 2014 (as amended), by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JPMorgan Chase Bank, N.A., as the successor administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto.

EX-10.1 Exhibit 10.1 Execution Version AMENDMENT NO. 10 TO AMENDED AND RESTATED CREDIT AGREEMENT AMENDMENT NO. 10 TO AMENDED AND RESTATED CREDIT AGREEMENT, dated as of November 22, 2023 (this “Amendment”), by and among CATALENT PHARMA SOLUTIONS, INC., a Delaware corporation (the “Borrower”), PTS INTERMEDIATE HOLDINGS LLC, a Delaware limited liability company (“Holdings”), the SUBSIDIARY GUARANTORS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2023 CATALENT, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2023 CATALENT, INC.

Catalent, Inc. Reports Preliminary First Quarter Fiscal 2024 Results and Reaffirms Full-Year Fiscal 2024 Guidance

Exhibit 99.1 Investor Contact: Catalent, Inc. Paul Surdez 732-537-6325 [email protected] Catalent, Inc. Reports Preliminary First Quarter Fiscal 2024 Results and Reaffirms Full-Year Fiscal 2024 Guidance •Q1'24 net revenue of $982 million decreased 4% as reported, or 6% in constant currency(1), compared to Q1'23. Organic, constant-currency net revenue decreased by 8%, compared to Q1'23. •Q1'24

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2023 ☐

NT 10-Q OMB APPROVAL OMB NUMBER 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response 2.

CTLT / Catalent Inc. / Capital World Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Catalent, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 148806102 (CUSIP Number) September 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des

Amendment No. 9 to Amended and Restated Credit Agreement, dated as of September 27, 2023, by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JPMorgan Chase Bank, N.A., as the administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto, which amends that certain Amended and Restated Credit Agreement, dated as of May 20, 2014 (as amended), by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JPMorgan Chase Bank, N.A., as the successor administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto.

EX-10.1 Exhibit 10.1 Execution Version AMENDMENT NO. 9 TO AMENDED AND RESTATED CREDIT AGREEMENT AMENDMENT NO. 9 TO AMENDED AND RESTATED CREDIT AGREEMENT, dated as of September 27, 2023 (this “Amendment”), by and among CATALENT PHARMA SOLUTIONS, INC., a Delaware corporation (the “Borrower”), PTS INTERMEDIATE HOLDINGS LLC, a Delaware limited liability company (“Holdings”), the SUBSIDIARY GUARANTORS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 28, 2023 (September 27, 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 28, 2023 (September 27, 2023) CATALENT, INC.

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

Exhibit 99.1 PRESS RELEASE Catalent Receives NYSE Notice Regarding Late Form 10-K Filing SOMERSET, N.J., September 15, 2023 – Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that, on September 14, 2023, it received a notice (the “NYSE Notice”) from the New York Stock Exchange (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 15, 2023 (September 14, 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 15, 2023 (September 14, 2023) CATALENT, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 10, 2023 CATALENT, INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 10, 2023 CATALENT, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Trans

OMB APPROVAL OMB NUMBER 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response 2.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 28, 2023 CATALENT, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 28, 2023 CATALENT, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive

Catalent Announces Governance Enhancements and New Initiatives to Drive Value Adding Four New Independent Directors Appoints John Greisch as Executive Chair Establishes New Strategic and Operational Review Committee of the Board Enters into Cooperati

EX-99.1 Exhibit 99.1 Catalent Announces Governance Enhancements and New Initiatives to Drive Value Adding Four New Independent Directors Appoints John Greisch as Executive Chair Establishes New Strategic and Operational Review Committee of the Board Enters into Cooperation Agreement with Elliott Investment Management L.P. SOMERSET, N.J.– August 29, 2023 — Catalent, Inc. (NYSE: CTLT), the leader in

Catalent, Inc. Reports Preliminary Fourth Quarter and Fiscal 2023 Results

Exhibit 99.1 Investor Contact: Catalent, Inc. Paul Surdez 732-537-6325 [email protected] Catalent, Inc. Reports Preliminary Fourth Quarter and Fiscal 2023 Results •Q4'23 net revenue of $1.07 billion decreased (17)% as reported, or (17)% in constant currency, compared to Q4'22. Organic, constant-currency net revenue decreased (19)%, compared to Q4'22. •Fiscal 2023 net revenue of $4.28 billion

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 29, 2023 CATALENT, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 29, 2023 CATALENT, INC.

Cooperation Agreement, dated as of August 28, 2023, by and among Elliott Investment Management L.P., a Delaware limited partnership, Elliott Associates, L.P., a Delaware limited partnership, and Elliott International, L.P., a Cayman Islands limited partnership, and Catalent, Inc., a Delaware corporation

EX-10.1 Exhibit 10.1 COOPERATION AGREEMENT This Cooperation Agreement (this “Agreement”), dated as of August 28, 2023 (the “Effective Date”), is by and among Elliott Investment Management L.P., a Delaware limited partnership, Elliott Associates, L.P., a Delaware limited partnership, and Elliott International, L.P., a Cayman Islands limited partnership (each, an “Elliott Party,” and, together, the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2023 CATALENT, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2023 CATALENT, INC.

Amendment No. 8 to Amended and Restated Credit Agreement, dated as of June 27, 2023, by JP Morgan Chase Bank, N.A., as the administrative agent, which amends that certain Amended and Restated Credit Agreement, dated as of May 20, 2014 (as amended), by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JP Morgan Chase Bank, N.A., as the administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto.

EX-10.1 Exhibit 10.1 Execution Version LIBOR HARDWIRE TRANSITION AMENDMENT AMENDMENT NO. 8 TO AMENDED AND RESTATED CREDIT AGREEMENT THIS AMENDMENT NO. 8. (this “Agreement”), dated as of June 27, 2023, is executed and delivered by JPMORGAN CHASE BANK, N.A., as administrative agent (in such capacity, the “Administrative Agent”) and as collateral agent, pursuant to Section 3.03(d) of that certain Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 20, 2023 CATALENT, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 20, 2023 CATALENT, INC.

Catalent Appoints Matti Masanovich Senior Vice President & Chief Financial Officer

EX-99.1 Exhibit 99.1 Catalent Appoints Matti Masanovich Senior Vice President & Chief Financial Officer SOMERSET, N.J., June 20, 2023 – Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that Matti Masanovich has been named Senior Vice President & Chief Financial Officer, effective July 5, 2023. Prior to joini

Offer letter, dated June 15, 2023, between Matti Masanovich and the Company.

EX-10.1 Exhibit 10.1 June 15, 2023 Matti Masanovich [Address on file with Company] Dear Matti: Congratulations on this offer to join our team! Catalent hires people with a passion to make a difference to the health of millions of people globally. Your expertise, coupled with Catalent’s expertise and capabilities and its collaborations with thousands of innovative pharmaceutical, biotech, and healt

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2023 CATALENT, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2023 CATALENT, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 o

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-36587 (Commission File Number) Catalent, Inc. (Exact name of regis

Catalent, Inc. Reports Third Quarter Fiscal 2023 Results

Exhibit 99.1 Investor Contact: Catalent, Inc. Paul Surdez 732-537-6325 [email protected] Catalent, Inc. Reports Third Quarter Fiscal 2023 Results •Q3'23 net revenue of $1.04 billion decreased 19% as reported, or 17% in constant currency(1), compared to Q3'22. Organic, constant-currency net revenue decreased by 19%, compared to Q3'22. •Q3'23 net loss of $(227) million, including a goodwill imp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 12, 2023 CATALENT, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 12, 2023 CATALENT, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No.1) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 or ¨ TRANSITION REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No.1) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36587 CATALENT,

BYLAWS CATALENT, INC. (Last revised FEBRUARY 2, 2023) ARTICLE I

EX-3.1 2 catalent-20230331xex31.htm EX-3.1 EXHIBIT 3.1 BYLAWS OF CATALENT, INC. (Last revised FEBRUARY 2, 2023) ARTICLE I Offices Section 1.01 Registered Office. The registered office and registered agent of Catalent, Inc. (the “Corporation”) in the State of Delaware shall be as set forth in the Corporation’s certificate of incorporation as then in effect (as the same may be amended or restated fr

Forward-looking Statements This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact, are, or may be deemed to be, forward- looking statements within the meaning of Section 27A

EX-99.2 Exhibit 99.2 Q3’23 Business Update May 19, 2023 Forward-looking Statements This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact, are, or may be deemed to be, forward- looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 19, 2023 (May 16, 2023) CATALEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 19, 2023 (May 16, 2023) CATALENT, INC.

Catalent to Hold Business Update Call Related to Delay of Third Quarter 2023 Results and Receives NYSE Notice Regarding Late Form 10-Q Filing

EX-99.1 Exhibit 99.1 PRESS RELEASE Catalent to Hold Business Update Call Related to Delay of Third Quarter 2023 Results and Receives NYSE Notice Regarding Late Form 10-Q Filing SOMERSET, N.J., May 19, 2023 – Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that, in light of the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2023 (May 12, 2023) CATALEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2023 (May 12, 2023) CATALENT, INC.

Catalent Announces Postponement of Third Quarter 2023 Results and Conference Call

EX-99.1 Exhibit 99.1 PRESS RELEASE Catalent Announces Postponement of Third Quarter 2023 Results and Conference Call SOMERSET, N.J., May 12, 2023 – Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that in light of the circumstances described in the Company’s Form 12b-25 filed on

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Tran

NT 10-Q SEC File Number 001-36587 CUSIP Number 148806102 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2023 (May 8, 2023) CATALENT,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2023 (May 8, 2023) CATALENT, INC.

Catalent Delays Third Quarter Results and Conference Call and Provides Update on Fiscal 2023 Guidance

EX-99.1 Exhibit 99.1 PRESS RELEASE Catalent Delays Third Quarter Results and Conference Call and Provides Update on Fiscal 2023 Guidance SOMERSET, N.J., May 8, 2023 – Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will be delaying the release of its third fiscal quarter results and investor confere

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 14, 2023 (April 13, 2023) CAT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 14, 2023 (April 13, 2023) CATALENT, INC.

Catalent Provides Business Update and Names Ricky Hopson as Interim Chief Financial Officer

EX-99.1 Exhibit 99.1 Catalent Provides Business Update and Names Ricky Hopson as Interim Chief Financial Officer SOMERSET, N.J., April 14, 2023 – Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced a business update. While complete financial information and operating data for the C

CTLT / Catalent Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Catalent, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 148806102 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi

CTLT / Catalent Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0529-catalentinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Catalent Inc. Title of Class of Securities: Common Stock CUSIP Number: 148806102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 1, 2023 CATALENT, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 1, 2023 CATALENT, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 202

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-36587 (Commission File Number) Catalent, Inc. (Exact name of re

Catalent, Inc. Reports Second Quarter Fiscal 2023 Results

Exhibit 99.1 Investor Contact: Catalent, Inc. Paul Surdez 732-537-6325 [email protected] Catalent, Inc. Reports Second Quarter Fiscal 2023 Results •Q2'23 net revenue of $1.15 billion decreased 6% as reported, or 2% in constant currency(1), compared to Q2'22. Organic, constant-currency net revenue decreased by 4%, compared to Q2'22. •Q2'23 net earnings of $81 million. •Q2'23 Adjusted EBITDA(1)

Bylaws of Catalent, Inc., effective February 2, 2023 (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on February 7, 2023).

EXHIBIT 3.2 BYLAWS OF CATALENT, INC. (Last revised FEBRUARY 2, 2023) ARTICLE I Offices Section 1.01 Registered Office. The registered office and registered agent of Catalent, Inc. (the “Corporation”) in the State of Delaware shall be as set forth in the Corporation’s certificate of incorporation as then in effect (as the same may be amended or restated from time to time, the “Certificate of Incorp

CTLT / Catalent Inc / Veritas Asset Management LLP Passive Investment

SC 13G 1 veritas-ctlt123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Catalent, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 148806102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 19, 2022 (December 14, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 19, 2022 (December 14, 2022) CATALENT, INC.

Catalent Announces Changes to its Board of Directors Board of Directors Selects J. Martin Carroll as Next Chair Executive Chair John Chiminski and Directors Rolf Classon and Peter Zippelius to Retire

EX-99.1 Exhibit 99.1 Catalent Announces Changes to its Board of Directors Board of Directors Selects J. Martin Carroll as Next Chair Executive Chair John Chiminski and Directors Rolf Classon and Peter Zippelius to Retire SOMERSET, N.J. — December 19, 2022 – Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and

Amendment No. 7 to Amended and Restated Credit Agreement, dated as of November 22, 2022, by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JP Morgan Chase Bank, N.A., as the administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto, which amends that certain Amended and Restated Credit Agreement, dated as of May 20, 2014 (as amended), by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JP Morgan Chase Bank, N.A., as the successor administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto.

Exhibit 10.1 Execution Version AMENDMENT NO. 7 TO AMENDED AND RESTATED CREDIT AGREEMENT AMENDMENT NO. 7 TO AMENDED AND RESTATED CREDIT AGREEMENT, dated as of November 22, 2022 (this ?Amendment?), by and among CATALENT PHARMA SOLUTIONS, INC., a Delaware corporation (the ?Borrower?), PTS INTERMEDIATE HOLDINGS LLC, a Delaware limited liability company (?Holdings?), the GUARANTORS, JPMORGAN CHASE BANK

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 22, 2022 CATALENT, INC.

PERFORMANCE SHARE UNIT AGREEMENT FOR NON-U.S. PARTICIPANTS UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN

Exhibit 10.7-7 PERFORMANCE SHARE UNIT AGREEMENT FOR NON-U.S. PARTICIPANTS UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN (Performance Period commencing on July 1, 2022 and ending on June 30, 2025) Pursuant to the Performance Share Unit Grant Notice for Non-U.S. Participants (the ?Grant Notice?) delivered to the Participant (as defined in the Grant Notice), and subject to the terms of this Pe

RESTRICTED STOCK UNIT AGREEMENT FOR NON-U.S. PARTICIPANTS UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN

Exhibit 10.7-3 RESTRICTED STOCK UNIT AGREEMENT FOR NON-U.S. PARTICIPANTS UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN Pursuant to the Restricted Stock Unit Grant Notice for Non-U.S. Participants (the ?Grant Notice?) delivered to the Participant (as defined in the Grant Notice), and subject to the terms of this Restricted Stock Unit Agreement for Non-U.S. Participants, including any special

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 20

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-36587 (Commission File Number) Catalent, Inc. (Exact name of r

Catalent, Inc. Reports First Quarter Fiscal 2023 Results

Exhibit 99.1 Investor Contact: Catalent, Inc. Paul Surdez 732-537-6325 [email protected] Catalent, Inc. Reports First Quarter Fiscal 2023 Results •Q1'23 net revenue of $1.02 billion, consistent with the prior-year period as reported, but increased 4% in constant currency, compared to Q1'22. Organic, constant-currency net revenue decreased by 1%, compared to Q1'22. •Q1'23 net earnings of zero.

RESTRICTED STOCK UNIT AGREEMENT UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN

Exhibit 10.7 RESTRICTED STOCK UNIT AGREEMENT UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN Pursuant to the Restricted Stock Unit Grant Notice (the ?Grant Notice?) delivered to the Participant (as defined in the Grant Notice), and subject to the terms of this Restricted Stock Unit Agreement (this ?Agreement?) and the Plan (as defined below), Catalent, Inc. (the ?Company?) and the Participant

July 27, 2022

July 27, 2022 Thomas Castellano Dear Tom, I am very pleased to share that the Compensation and Leadership Committee of the Board of Directors has approved an increase to your Total Direct Compensation (?TDC?) comprising your base salary, short-term cash incentive and long-term equity incentives.

Management Incentive Plan Summary for the fiscal year ending June 30, 2023 (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed on November 1, 2022). †

Exhibit 10.3 Management Incentive Plan FY2023 Summary Introduction The Management Incentive Plan (MIP) is a variable annual cash incentive program under the Catalent, Inc. 2018 Omnibus Incentive Plan (the Plan) that rewards performance against annual individual and business-based goals. Individual performance goals designed to support the broader business goals are established each year between el

DESCRIPTION OF CAPITAL STOCK

Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK The following is a description of the material terms of, and is qualified in its entirety by, our fourth amended and restated certificate of incorporation (the ?Certificate of Incorporation?) and our bylaws, both of which are filed as exhibits to our Annual Report on Form 10-K for the year ended June 30, 2022 (the ?2022 Annual Report?). Our purpose is to en

PERFORMANCE SHARE UNIT AGREEMENT UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN (Performance Period commencing on July 1, 2022 and ending on June 30, 2025)

Exhibit 10.7-6 PERFORMANCE SHARE UNIT AGREEMENT UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN (Performance Period commencing on July 1, 2022 and ending on June 30, 2025) Pursuant to the Performance Share Unit Grant Notice (the ?Grant Notice?) delivered to the Participant (as defined in the Grant Notice), and subject to the terms of this Performance Share Unit Agreement (this ?Agreement?), a

Catalent Pharma Solutions, Inc. Deferred Compensation Plan, as amended and restated effective October 1, 2022 (incorporated by reference to Exhibit 10.6 to the Company’s Quarterly Report on Form 10-Q filed on November 1, 2022). †

CATALENT PHARMA SOLUTIONS, INC. DEFERRED COMPENSATION PLAN Amended and Restated Effective October 1, 2022 Catalent Pharma Solutions, Inc. Deferred Compensation Plan ARTICLE 1 Establishment and Purpose Catalent Pharma Solutions, Inc. (the "Company") established the Catalent Pharma Solutions, LLC Deferred Compensation Plan, effective as of April 10, 2007 (the "CPS LLC Plan"). The CPS LLC Plan was su

RESTRICTED STOCK UNIT AGREEMENT UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN

Exhibit 10.7-2 RESTRICTED STOCK UNIT AGREEMENT UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN Pursuant to the Restricted Stock Unit Grant Notice (the ?Grant Notice?) delivered to the Participant (as defined in the Grant Notice), and subject to the terms of this Agreement (this ?Agreement?) and the Plan (as defined below), Catalent, Inc. (the ?Company?) and the Participant agree as follows. 1

RESTRICTED STOCK UNIT AGREEMENT FOR NON-U.S. NON-EMPLOYEE DIRECTORS UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN

EX-10.7-1 7 catalent-2022930ex1071.htm EX-10.7-1 Exhibit 10.7-1 RESTRICTED STOCK UNIT AGREEMENT FOR NON-U.S. NON-EMPLOYEE DIRECTORS UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN Pursuant to the Restricted Stock Unit Grant Notice for Non-U.S. Non-Employee Directors (the “Grant Notice”) delivered to the Participant (as defined in the Grant Notice), and subject to the terms of this Restricted

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2022 CATALENT, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2022 CATALENT, INC.

OPTION AGREEMENT FOR NON-U.S. PARTICIPANTS UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN

Exhibit 10.7-5 OPTION AGREEMENT FOR NON-U.S. PARTICIPANTS UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN Pursuant to the Option Grant Notice for Non-U.S. Participants (the ?Grant Notice?) delivered to the Participant (as defined in the Grant Notice), and subject to the terms of this Option Agreement for Non-U.S. Participants, including any special terms and conditions for the Participant?s c

OPTION AGREEMENT UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN

Exhibit 10.7-4 OPTION AGREEMENT UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN Pursuant to the Option Grant Notice (the ?Grant Notice?) delivered to the Participant (as defined in the Grant Notice), and subject to the terms of this Option Agreement (this ?Agreement?) and the Plan (as defined below), Catalent, Inc. (the ?Company?) and the Participant agree as follows. 1.Definitions. Whenever

As filed with the Securities and Exchange Commission on September 28, 2022.

Table of Contents As filed with the Securities and Exchange Commission on September 28, 2022.

Form of Indenture.

Exhibit 4.4 CATALENT, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Section 2.03

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Catalent, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Fo

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 19, 2022 CATALENT, INC.

August 29, 2022

August 29, 2022 Karen Santiago [Address on file with Company] Dear Karen: Congratulations on your offer to join our growing team! Catalent hires people with a passion to make a difference to the health of millions of people globally.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 9, 2022 CATALENT, INC.

Catalent Appoints Karen Santiago as Vice President and Chief Accounting Officer

14 Schoolhouse Road Somerset NJ 08873 USA catalent.com + 1 888 SOLUTION (76588466) Press Release Contacts: Media Investor Relations Chris Halling +44 (0)7580 041073 [email protected] Paul Surdez +1 (732) 537 6325 [email protected] Catalent Appoints Karen Santiago as Vice President and Chief Accounting Officer SOMERSET, N.J. ? September 19, 2022 ? Catalent, the global leader in enabli

Schedule 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36587 CATALENT, INC. (Exact name of

EX-10.12.1

July 7, 2022 Steven Fasman 27 Club Pointe Dr White Plains, NY 10605 Dear Steven: Congratulations on your promotion to Executive Vice President and Chief Administrative Officer (EVP and CAO).

14 Schoolhouse Road Somerset, New Jersey

14 Schoolhouse Road Somerset, New Jersey 08873 catalent.com + 1 888 SOLUTION (76588466) March 15, 2018 Aristippos Gennadios 300 Beach Drive NE Apt. 904 St. Petersburg, FL 33701 USA Dear Aristippos: From time to time we review all Executive Leadership Team offer letters. This letter amends previous offer letters and is effective immediately. The following is important information about your individ

CATALENT, INC. SUBSIDIARIES As of June 30, 2022

Exhibit 21.1 Attachment A CATALENT, INC. SUBSIDIARIES As of June 30, 2022 NAME (STATE/COUNTRY OF ORGANIZATION) WHOLLY OWNED SUBSIDIARIES OF CATALENT, INC. (UNLESS OTHERWISE INDICATED) 1 Catalent Anagni S.r.l. (ITALY) 2 Catalent Argentina S.A.I.C. (ARGENTINA) 3 Catalent Belgium S.A. (BELGIUM) 4 Catalent Belgium Holding S.A. (BELGIUM) 5 Catalent Brasil Ltda (BRAZIL) 6 Catalent China Holdings Limited

Catalent, Inc. Reports Fourth Quarter Fiscal 2022 Results

Exhibit 99.1 Investor Contact: Catalent, Inc. Paul Surdez 732-537-6325 [email protected] Catalent, Inc. Reports Fourth Quarter Fiscal 2022 Results ?Q4'22 net revenue of $1.31 billion increased 10% as reported, or 15% in constant currency, compared to Q4'21. Organic, constant-currency net revenue grew 10%, compared to Q4'21. ?Fiscal 2022 net revenue of $4.83 billion increased 21% as reported,

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 29, 2022 CATALENT, INC.

EX-10.13.1

July 7, 2022 Aris Gennadios 300 Beach Drive NE Apt. 904 St. Petersburg, FL 33701 Dear Aris: Congratulations on your promotion to Group President, Pharma & Consumer Health. This letter amends and restates previous offer letters, effective July 1, 2022. The following is important information about your new position, benefits, and rewards. I encourage you to review all materials thoroughly and contac

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 1, 2022 CATALENT, INC.

Catalent Announces New Operating Structure Company Consolidates from Four Reporting Segments to Two, One Focusing on Biologics and the Other on Pharmaceuticals and Consumer Health

Exhibit 99.1 Press Release Media Contact: Investor Contact: Chris Halling +44 (0)7580 041073 [email protected] Paul Surdez +1 (732) 537-6325 [email protected] Catalent Announces New Operating Structure Company Consolidates from Four Reporting Segments to Two, One Focusing on Biologics and the Other on Pharmaceuticals and Consumer Health SOMERSET, N.J. ? July 5, 2022 ? Catalent, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 o

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-36587 (Commission File Number) Catalent, Inc. (Exact name of regis

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 3, 2022 CATALENT, INC.

Catalent, Inc. Reports Third Quarter Fiscal 2022 Results

Exhibit 99.1 Investor Contact: Catalent, Inc. Paul Surdez 732-537-6325 [email protected] Catalent, Inc. Reports Third Quarter Fiscal 2022 Results ?Q3'22 net revenue of $1.27 billion increased 21% as reported, or 23% in constant currency, compared to Q3'21. Organic, constant-currency net revenue grew 20%, compared to Q3'21. ?Q3'22 net earnings of $141 million. ?Q3'22 Adjusted EBITDA(1) of $339

CTLT / Catalent Inc / Capital World Investors - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Catalent, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 148806102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule

CTLT / Catalent Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Catalent Inc. Title of Class of Securities: Common Stock CUSIP Number: 148806102 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule

Calculation of Filing Fee Table (Form Type) Catalent, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-233756 Calculation of Filing Fee Table 424B5 (Form Type) Catalent, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount

Bylaws of Catalent, Inc., effective January 27, 2022 (incorporated by reference to Exhibit 3.2 to the Catalent, Inc.’s Current Report on Form 8-K filed on February 1, 2022).

EXHIBIT 3.2 BYLAWS OF CATALENT, INC. (LAST REVISED JANUARY 27, 2022) ARTICLE I Offices Section 1.01 Registered Office. The registered office and registered agent of Catalent, Inc. (the ?Corporation?) in the State of Delaware shall be as set forth in the Corporation?s certificate of incorporation as then in effect (as the same may be amended or restated from time to time, the ?Certificate of Incorp

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 27, 2022 CATALENT, INC.

Catalent, Inc. Reports Second Quarter Fiscal 2022 Results

Exhibit 99.1 Investor Contact: Catalent, Inc. Paul Surdez 732-537-6325 [email protected] Catalent, Inc. Reports Second Quarter Fiscal 2022 Results ?Q2'22 net revenue of $1.22 billion increased 34% as reported, or 35% in constant currency, compared to Q2'21. Organic, constant-currency net revenue grew 32%, compared to Q2'21. ?Q2'22 net earnings of $97 million. ?Q2'22 Adjusted EBITDA(1) of $310

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 202

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-36587 (Commission File Number) Catalent, Inc. (Exact name of re

Amended and Restated Employment Agreement, dated January 4, 2022, by and between Catalent, Inc. and John R. Chiminski.

EXHIBIT 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT (John R. Chiminski) This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?), dated as of January 4, 2022 (the ?Effective Date?), is being entered into by and between Catalent, Inc. (together with its successors and assigns, the ?Company?) and John R. Chiminski (?Executive? and, together with the Company, each a ?Party? and collectivel

More products. Better treatments. Reliably supplied.™

EXHIBIT 99.1 Catalent Announces Plan for Alessandro Maselli to Become New CEO Effective July 1, 2022 SOMERSET, N.J. ? January 5, 2022 ? Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, as well as consumer health products, today announced that its Board of Directors has ap

Employment Agreement, dated January 4, 2022, by and between Catalent, Inc. and Alessandro Maselli.

EXHIBIT 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?), dated January 4, 2022 (the ?Effective Date?), is being entered into by and between Catalent, Inc. (together with its successors and assigns, the ?Company?) and Alessandro Maselli (?Executive? and, together with the Company, each a ?Party? and collectively the ?Parties?). WHEREAS, Executive has been employed by wholly ow

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 4, 2022 CATALENT, INC.

BYLAWS OF CATALENT, INC. (LAST REVISED OCTOBER 28, 2021) ARTICLE I Offices

BYLAWS OF CATALENT, INC. (LAST REVISED OCTOBER 28, 2021) ARTICLE I Offices Section I.01Registered Office. The registered office and registered agent of Catalent, Inc. (the ?Corporation?) in the State of Delaware shall be as set forth in the Corporation?s certificate of incorporation as then in effect (as the same may be amended or restated from time to time, the ?Certificate of Incorporation?). Th

Fourth Amended and Restated Certificate of Incorporation of Catalent, Inc., as filed with the Secretary of State of the State of Delaware on October 28, 2021 (incorporated by reference to Exhibit 3.1 to the Catalent, Inc.’s Current Report on Form 8-K filed on November 2, 2021).

FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CATALENT, INC. The present name of the corporation is Catalent, Inc. (the ?Corporation?). The Corporation was incorporated under the name ?PTS Holdings Corp.? by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on March 14, 2007, which original Certificate of Incorporation was am

Catalent, Inc. Reports First Quarter Fiscal 2022 Results

EX-99.1 4 earningsreleaseex991-fy22x.htm EX-99.1 Exhibit 99.1 Investor Contact: Catalent, Inc. Paul Surdez 732-537-6325 [email protected] Catalent, Inc. Reports First Quarter Fiscal 2022 Results •Q1'22 net revenue of $1.03 billion increased 21% as reported, or 20% in constant currency, compared to Q1'21. Organic, constant-currency net revenue grew 23%, compared to Q1'21. •Q1'22 net earnings o

Management Incentive Plan FY2022 Summary

Exhibit 10.2 Management Incentive Plan FY2022 Summary Introduction The Management Incentive Plan (MIP) is a variable annual cash incentive program under the Catalent, Inc. 2018 Omnibus Incentive Plan (the Plan) that rewards performance against annual individual and business-based goals. Individual performance goals designed to support the broader business goals are established each year between el

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2021 CATALENT, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 20

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-36587 (Commission File Number) Catalent, Inc. (Exact name of r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

Indenture, dated September 29, 2021, by and among Catalent Pharma Solutions, Inc., the subsidiary guarantors named therein, and Deutsche Bank Trust Company Americas, as trustee.

Exhibit 4.1 Execution Version INDENTURE Dated as of September 29, 2021 among CATALENT PHARMA SOLUTIONS, INC. the Guarantors listed herein DEUTSCHE BANK TRUST COMPANY AMERICAS as Trustee 3.500% SENIOR NOTES DUE 2030 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND RULES OF CONSTRUCTION SECTION 1.01. Definitions 1 SECTION 1.02. Other Definitions 41 SECTION 1.03. Rules of Construction and Incorporati

Amendment No. 6 to Amended and Restated Credit Agreement, dated as of September 29, 2021, by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JP Morgan Chase Bank, N.A., as the administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto, which amends that certain Amended and Restated Credit Agreement, dated as of May 20, 2014 (as amended), by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JP Morgan Chase Bank, N.A., as the successor administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto.

Exhibit 10.1 AMENDMENT NO. 6 TO AMENDED AND RESTATED CREDIT AGREEMENT AMENDMENT NO. 6 TO AMENDED AND RESTATED CREDIT AGREEMENT, dated as of September 29, 2021 (this ?Amendment?), by and among CATALENT PHARMA SOLUTIONS, INC., a Delaware corporation (the ?Borrower?), PTS INTERMEDIATE HOLDINGS LLC, a Delaware limited liability company (?Holdings?), the GUARANTORS, JPMORGAN CHASE BANK, N.A., as Admini

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 29, 2021 CATALENT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36587 20-8737688 (State or other jurisdiction of Incorporation) (Commission File

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 23, 2021 CATALENT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36587 20-8737688 (State or other jurisdiction of Incorporation) (Commission File

Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2030

Exhibit 99.1 Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2030 SOMERSET, N.J., September 23, 2021?Catalent, Inc. (?Catalent?) (NYSE: CTLT), the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, today announced that its wholly owned

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 23, 2021 CATALENT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36587 20-8737688 (State or other jurisdiction of Incorporation) (Commission File

Catalent Announces Launch of Private Offering of $450 Million of Senior Unsecured Notes Due 2030

Exhibit 99.1 Catalent Announces Launch of Private Offering of $450 Million of Senior Unsecured Notes Due 2030 SOMERSET, N.J., September 23, 2021 ? Catalent, Inc. (?Catalent?) (NYSE: CTLT), the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, today announced that its wholly ow

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitt

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

Membership Interest Purchase Agreement, dated August 29, 2021, by and among Catalent Pharma Solutions, Inc., Bettera Holdings, LLC, the members of Bettera Holdings, LLC, and Highlander Partners Candy, LLC.

Exhibit 2.1 EXECUTION COPY MEMBERSHIP INTEREST PURCHASE AGREEMENT by and among CATALENT PHARMA SOLUTIONS, INC. as Buyer BETTERA HOLDINGS, LLC, as the Company THE MEMBERS OF THE COMPANY, as the Sellers and HIGHLANDER PARTNERS CANDY, LLC, as the Representative dated as of August 29, 2021 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 ARTICLE II PURCHASE AND SALE 13 Section 2.01 Purchase and Sale 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 29, 2021 CATALENT, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 29, 2021 CATALENT, INC.

CATALENT, INC. SUBSIDIARIES As of June 30, 2021

EX-21.1 2 catalent-2021630xex211.htm EX-21.1 Exhibit 21.1 Attachment A CATALENT, INC. SUBSIDIARIES As of June 30, 2021 NAME (STATE/COUNTRY OF ORGANIZATION) WHOLLY OWNED SUBSIDIARIES OF CATALENT, INC. (UNLESS OTHERWISE INDICATED) 1 Catalent Anagni S.r.l. (ITALY) 2 Catalent Argentina S.A.I.C. (ARGENTINA) 3 Catalent Belgium Holding S.A. (BELGIUM) 4 Catalent Belgium S.A. (BELGIUM) 5 Catalent Brasil Lt

Catalent to Extend Leadership in Rapidly Growing Nutraceuticals Market with Proposed $1 Billion Acquisition of Bettera, a Leading Gummies Manufacturer

EXHIBIT 99.2 14 Schoolhouse Road Somerset NJ 08873 USA catalent.com + 1 888 SOLUTION (76588466) Catalent to Extend Leadership in Rapidly Growing Nutraceuticals Market with Proposed $1 Billion Acquisition of Bettera, a Leading Gummies Manufacturer SOMERSET, N.J. ? August 30, 2021 ? Catalent, Inc. (NYSE: CTLT), the leading global provider of development sciences and manufacturing platforms for medic

Catalent, Inc. Reports Fourth Quarter Fiscal 2021 Results

Exhibit 99.1 Investor Contact: Catalent, Inc. Paul Surdez 732-537-6325 [email protected] Catalent, Inc. Reports Fourth Quarter Fiscal 2021 Results ? Q4?21 net revenue of $1.19 billion increased 25% as reported, or 22% in constant currency, compared to Q4?20. Organic, constant-currency net revenue grew 26%, compared to Q4?20. ? Fiscal 2021 net revenue of $4.00 billion increased 29% as reported

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 or ¨ TRANSITION REPORT PURSUANT TO SECTIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36587 CATALENT, INC. (Exact name of

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 17, 2021 CATALENT, INC.

Offer letter, dated May 17, 2021, between Ricky Hopson and Catalent Pharma Solutions, Inc.

Exhibit 10.1 May 17, 2021 Ricky Hopson [Address on file with Company] Dear Ricky: Congratulations on your promotion to Vice President & Chief Accounting Officer (VP CAO). This letter amends and restates previous offer letters and is effective June 1, 2021. The following is important information about your new position, benefits and rewards. I encourage you to review all materials thoroughly and co

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2021 CATALENT, INC.

Offer letter, dated May 10, 2021, between Thomas Castellano and Catalent Pharma Solutions, Inc.

Exhibit 10.1 May 10, 2021 Tom Castellano [Address on file with Company] USA Dear Tom: Congratulations on your promotion to Senior Vice President & Chief Financial Officer (SVP CFO). This letter amends and restates previous offer letters and is effective June 1, 2021. The following is important information about your new position, benefits and rewards. I encourage you to review all materials thorou

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2021 CATALENT, INC.

Catalent, Inc. Reports Third Quarter Fiscal 2021 Results

Exhibit 99.1 Earnings Release Investor Contact: Catalent, Inc. Paul Surdez 732-537-6325 [email protected] Catalent, Inc. Reports Third Quarter Fiscal 2021 Results ?Q3'21 net revenue of $1.05 billion increased 38% as reported, or 35% in constant currency, compared to Q3'20. Organic, constant-currency net revenue grew 35%, compared to Q3'20. ?Q3'21 net earnings of $232 million; includes a $184

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-36587 (Commission File Number) Catalent, Inc. (Exact name of regis

Amendment No. 5 to Amended and Restated Credit Agreement, dated as of February 22, 2021, by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JP Morgan Chase Bank, N.A., as the administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto, which amends that certain Amended and Restated Credit Agreement, dated as of May 20, 2014 (as amended), by and among Catalent Pharma Solutions, Inc., PTS Intermediate Holdings LLC, JP Morgan Chase Bank, N.A., as the successor administrative agent, collateral agent, swing line lender, and letter of credit issuer, and the lenders and other parties thereto.

Exhibit 10.1 Execution Version AMENDMENT NO. 5 TO AMENDED AND RESTATED CREDIT AGREEMENT AMENDMENT NO. 5 TO AMENDED AND RESTATED CREDIT AGREEMENT, dated as of February 22, 2021 (this ?Amendment?), by and among CATALENT PHARMA SOLUTIONS, INC., a Delaware corporation (the ?Borrower?), PTS INTERMEDIATE HOLDINGS LLC, a Delaware limited liability company (?Holdings?), the GUARANTORS, JPMORGAN CHASE BANK

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 22, 2021 CATALENT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36587 20-8737688 (State or other jurisdiction of Incorporation) (Commission File N

Indenture, dated February 22, 2021, by and among Catalent Pharma Solutions, Inc., the subsidiary guarantors named therein, and Deutsche Bank Trust Company Americas, as trustee.

Exhibit 4.1 Execution Version INDENTURE Dated as of February 22, 2021 among CATALENT PHARMA SOLUTIONS, INC. the Guarantors listed herein DEUTSCHE BANK TRUST COMPANY AMERICAS as Trustee 3.125% SENIOR NOTES DUE 2029 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND RULES OF CONSTRUCTION SECTION 1.01. Definitions 1 SECTION 1.02. Other Definitions 40 SECTION 1.03. Rules of Construction and Incorporatio

Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2029

EX-99.1 Exhibit 99.1 Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2029 SOMERSET, N.J., February 10, 2021—Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that its wh

Financial Statements and Exhibits, Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 10, 2021 CATALENT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36587 20-8737688 (State or other jurisdiction of Incorporation) (Commission File N

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Catalent Inc. Title of Class of Securities: Common Stock CUSIP Number: 148806102 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule

Catalent Announces Launch of Private Offering of $475 Million of Senior Unsecured Notes Due 2029

EX-99.1 Exhibit 99.1 Catalent Announces Launch of Private Offering of $475 Million of Senior Unsecured Notes Due 2029 SOMERSET, N.J., February 10, 2021 — Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it

Financial Statements and Exhibits, Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 10, 2021 CATALENT, INC. (Exact name of registrant as specified in its charter) Delaware 001-36587 20-8737688 (State or other jurisdiction of Incorporation) (Commission File N

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-36587 (Commission File Number) Catalent, Inc. (Exact name of re

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 2, 2021 CATALENT, INC.

Catalent, Inc. Reports Second Quarter Fiscal 2021 Results

Exhibit 99.1 Earnings Release Investor Contact: Catalent, Inc. Paul Surdez 732-537-6325 [email protected] Catalent, Inc. Reports Second Quarter Fiscal 2021 Results •Q2'21 net revenue of $910.8 million increased 26% as-reported, or 24% in constant currency, compared to Q2'20. Organic, constant currency net revenue grew 17%, compared to Q2'20. •Q2'21 net earnings of $88.4 million increased 94%,

CTLT / Catalent Inc. / Green Equity Investors VII, L.P. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Catalent, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 148806102 (CUSIP Number) Jennifer Bellah Maguire Gibson, Dunn & Crutcher LLP 333 South Grand Avenue Los Angeles, California 90071-3197 (213) 2

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 29, 2020 CATALENT, INC.

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-36587 (Commission File Number) Catalent, Inc. (Exact name of r

Management Incentive Plan FY2021 Summary

Exhibit 10.1 Management Incentive Plan FY2021 Summary Introduction The Management Incentive Plan (MIP) is a variable annual cash incentive program under the Catalent, Inc. 2018 Omnibus Incentive Plan (the Plan) that rewards performance against annual individual and business-based goals. Individual performance goals designed to support the broader business goals are established each year between el

Catalent, Inc. Reports First Quarter Fiscal 2021 Results

Exhibit 99.1 Earnings Release Investor Contact: Catalent, Inc. Paul Surdez 732-537-6325 [email protected] Catalent, Inc. Reports First Quarter Fiscal 2021 Results • Q1'21 net revenue of $845.7 million increased 27% as-reported, or 26% in constant currency, compared to Q1'20. On an organic basis, constant currency net revenue in Q1'21 grew 20% compared to Q1'20. • Q1'21 Adjusted EBITDA of $174

CTLT / Catalent Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Catalent Inc. Title of Class of Securities: Common Stock CUSIP Number: 148806102 Date of Event Which Requires Filing of this Statement: September 30, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule

- DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De

- DEFINITIVE PROXY STATEMENT

Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

CATALENT, INC. SUBSIDIARIES As of June 30, 2020

Exhibit 21.1 Attachment A CATALENT, INC. SUBSIDIARIES As of June 30, 2020 NAME (STATE/COUNTRY OF ORGANIZATION) WHOLLY OWNED SUBSIDIARIES OF CATALENT, INC. (UNLESS OTHERWISE INDICATED) 1 Catalent Anagni S.r.l. (ITALY) 2 Catalent Argentina S.A.I.C. (ARGENTINA) 3 Catalent Belgium Holding S.A. (BELGIUM) 4 Catalent Belgium S.A. (BELGIUM) 5 Catalent Brasil Ltda (BRAZIL) 6 Catalent China Holdings Limited

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36587 CATALENT, INC. (Exact name of

SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (John R. Chiminski)

Exhibit 10.12.2 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (John R. Chiminski) This SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”), is made and entered into effective as of August 11, 2020 (the “Amendment Effective Date”), by and between Catalent, Inc. (f/k/a PTS Holdings, Corp., together, with its successors and assigns, the “Company”) and John R. Chiminski (“Executive” and, together wi

RESTRICTED STOCK UNIT AGREEMENT UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN

Exhibit 10.5.4 RESTRICTED STOCK UNIT AGREEMENT UNDER THE CATALENT, INC. 2018 OMNIBUS INCENTIVE PLAN Pursuant to the Restricted Stock Unit Grant Notice (the “Grant Notice”) delivered to the Participant (as defined in the Grant Notice), and subject to the terms of this Restricted Stock Unit Agreement (this “Agreement”) and the Plan (as defined below), Catalent, Inc. (the “Company”) and the Participa

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 31, 2020 CATALENT, INC.

November 20, 2019

Exhibit 10.15 November 20, 2019 XXXXX Dear Karen: Congratulations on your offer to join our growing team! Catalent hires people with a passion to make a difference to the health of millions of people globally. Your expertise, coupled with Catalent’s advanced technologies and collaboration with thousands of innovative pharmaceutical, biotech and healthcare companies, will help bring life-enhancing